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Kaposi's Sarcoma (KS) remains an enigma over 100 years
after it was first described by a Hungarian dermatologist who
ensured his place in the hall of fame by changing his name to
the exotic 'Kaposi', marrying his Professor's daughter, and
describing one of the most enigmatic of all cancers. Indeed
there are considerable doubts as to whether or not KS is a
true cancer. Atypical and mitotic cells are extremely rare
histological findings and the multiple lesions which are such a
predominant feature do not really fit the classical under-
standing of metastases. Nevertheless the patient suffering
from advanced KS involving his gastrointestinal and respira-
tory tracts who is shortly to expire with a massive haemorr-
hage is hardly likely to be encouraged by the semantic
argument that he does not have cancer after all! (Zeigler &
Dorfman, 1988).
KS presents in a variety of guises. Until the HIV epidemic,
KS was most common in elderly men of Jewish or East
European origin where it presented as a multicentric pig-
mented 'sarcoma' usually appearing on the legs. It is hard to
exaggerate the indolence of KS for it responds to minimal
doses of radiotherapy or chemotherapy and the experience of
the oncologist who treats KS is demonstrated by the fact that
he or she usually only treats cosmetically appropriate lesions.
Certainly the wait and see approach is compatible with the
patient surviving many years and dying of another disease of
old age with the KS intact.
An endemic form of KS was recognised in Central and
Eastern Africa from the mid 1950's (Templeton, 1973). Dis-
parate clinical features are recognised in a classification de-
scribing four main types: Nodular (benign and slow growing),
florid (exophytic version of the nodular form), infiltrative
(dense with invasion of the dermis and bone) and lympha-
dermopathic (predominantly in children with rare cutaneous
lesions). A systemic subclassification similar to that used in
Hodgkin's disease has since been added with A and B indi-
cating absence and presence of systemic symptoms respec-
tively. Even in Africa, marked epidemiological localisation of
KS within regions, tribes and amongst individuals strongly
suggests a transmissible infectious agent. This does not ex-
clude however a genetic component to disease susceptibility.
No obvious factors have been implemented at the time of
writing although there are numerous tantalising clues the
most important of which will be reviewed here.
Immunosuppression plays an important role in the
development of KS which is recognised as a late complica-
tion of patients receiving organ transplants and accounts for
about 5% of the malignancies in this population (Penn, 1983,
1979). Although there appears to be an incubation time of
about 16 months post transplantation it is intriguing that the
lesions usually regress when immunosuppression is reduced.
The other association with immunosuppression is the appear-
ance in the 1980's of KS in about 40% of AIDS cases. This
association hides some interesting clues. Firstly the propor-
tion of KS in homosexuals with AIDS has gradually fallen to
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about 20% (is this due to safe sex or the reduction in a
co-factor, e.g. the use of a vasodilator like amyl nitrate which
was common in the gay community in the 1980's) and
secondly other groups infected with HIV tend not to get KS,
such as haemophiliacs and drug addicts (Rutherford et al.,
1990). Initially it was thought that heterosexuals with AIDS
did not get KS. However, this is clearly not the case now.
HIV seropositivity is associated with the aggressive systemic
and rapidly fatal KS in Africa (Whereas most 'classical' KS
cases are HIV negative) (Bayley et al., 1985). In Africa,
HIV is probably contracted from heterosexual contact, as
intensive studies have failed to demonstrate any significant
transmission by homosexual, intravenous drug abuse, conta-
minated blood products or insect bites (Serwadda et al.,
1985). Moreover, occasional HIV seropositive prostitutes are
beginning to present with KS lesions in Western cities.
Nevertheless, even in Africa the male predominance has been
noted since the disease was first recognised there.
Aetiology
Genetic
Early studies indicated a link between KS and HLA.DR5.
Further analysis of those reports suggests that the association
of HLA.DR5 with Italian or Ashkenzai Jewish descent may
explain the apparent association between DR5 and KS
(Papasteriades et al., 1984; Pollack et al., 1983a,b, 1985). In
Caucasian populations in which DR5 is less common, no
association with KS is seen. In the USA certain HLA
antigens (B35, C4, DRI and DQ1) were found to be more
frequent in the KS population compared to controls (Mann
et al., 1990). DR14 and DR53 are more frequent and HLA,
B8, C5 and DR3 are less frequent in KS patients than in
AIDS patients with opportunistic infections, but not with
KS. Several studies report other associations between HLA
and KS but these vary considerably depending on the
populations studied. Described associations include positive
links with DRI, DR2 but low frequency DR3 in KS patients.
Overall these studies do suggest that there is a genetic
component to KS which probably affects the response to an
infectious or other agent.
Infectious agents
The argument for an infectious aetiology is compelling and
includes the aforementioned clustering of cases in Africa
(Beral et al., 1990). However, evidence suggests that HIV
itself is not the direct cause. KS has been reported in sexually
active homosexual patients who have consistently remained
HIV sero negative (Friedman-Kien et al., 1990). As men-
tioned, HIV sero positive homosexuals tend to get KS, but
drug addicts do not. Female sexual partners of bisexual men
are much more likely to develop KS than the female partners
of intravenous drug abusers. A number of large cohort
studies have been published describing the associations with
the development of KS in AIDS patients. There are some
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inconsistencies. For example, an association with amyl nit-
rates was found in some studies (Mathur Wagh, 1985; Haver-
kos, 1985, 1987; Osmond, 1985) but not in others (Goedert et
al., 1986; Polk et al., 1987; Darrow et al., 1987). However
there was a strong implicative association with increased
numbers of partners, anoreceptive and 'rimming' practices,
and previous episodes of other sexually transmitted diseases.
The decline in the incidence of KS in the homosexual com-
munities has followed the introduction of safe sex campaigns
and are probably related.
Early studies associated Cytomegalovirus (CMV) with KS
(Giraldo et al., 1980). However, more stringent studies have
failed to confirm this association. Tissues from KS have now
been probed for a large number of known viruses including
HIV and other retroviruses as well as DNA tumour viruses.
No association has been shown. Attempts to isolate a novel
virus from KS patients have been unrewarding. Early reports
of a viral-like agent turned out to be mycoplasma although it
is still under consideration as having a causative role by its
discoverers (Lo et al., 1986). Recently however a retroviral
like agent has been reported in some KS specimens and a
claim been made that is causally associated (Rappersberger,
1990). However, the literature is littered with reports of virus
disease associations which have never been substantiated.
Meanwhile innovative approaches in the laboratory have
shed new light onto the pathogenesis of KS.
Growth factors
Salahuddin and colleagues working in Gallo's laboratory
attempted to overcome the long standing problem of growing
and maintaining KS cells in culture in vitro. They identified a
growth factor in the medium of HTLV-II infected cells which
supported the temporary growth of normal vascular endothe-
lial cells, but not fibroblasts (Nakarmura et al., 1988). Inter-
leukin I and tumour necrosis factor stimulated the growth of
KS cells transiently and could be distinguished from the
HTLV-II derived factor. The cells supported with this factor
were shown to be similar to the spindle cells in KS lesions
sharing some of the features. They produced factors that
supported their own growth (autocrine) and the growth of
other cells (paracrine) including umbilical vein endothelium
and fibroblasts. The angiogenic activity of these factors were
demonstrated by the development of KS like lesions (of
mouse origin yet similar to the human lesions) in nude mice
following subcutaneous innoculation (Salahuddin et al.,
1988). Further studies have shown that KS cells are more
susceptible to these factors than normal endothelial cells and
that they appear to be in an activated state with increased
levels of mRNA for many known growth factors (Ensoli et
al., 1989). This could suggest that KS cells are activated by a
virus infection or other event which makes them more
susceptible to second events such as exposure to growth
factors. An anology might be drawn to the way in which
HTLV-1 activates T cells and EBV activates B cells making
them prone to malignant transformation (Dalgleish & Mal-
kovsky, 1988). The role of HIV in KS patients has hitherto
been associated with immunosuppression and was thought to
be analogous to the development of KS in immunosuppress-
ed post organ transplant patients. However, transgenic mice
containing only the tat (the potent transactivating gene of
HIV) mainifest KS like lesions. Intriguingly only male mice
are affected and the skin is the only tissue to contain tat
mRNA (Vogel et al., 1988). Nevertheless KS occurs in HIV
negative individuals and interpretation of these results
requires considerable caution.
Basic biology
Normal angiogenesis generates new blood vessels most evi-
dent in wound healing and is a feature of diabetic retino-
pathy, haemangiomas, rheumatoid arthritis and tumours.
Endothelial cells involved in angiogenesis respond to fibro-
blastic growth factors and heparin like molecules. Negative
regulation is important and may in a large part be due to the
secretion of transforming growth factor beta (TGF-b) by
pericytes and vascular smooth muscle cells as TGF-b is a
potent inhibitor of angiogenic factors. The KS factor des-
cribed by Salahuddin et al. (1988) may be an abnormal form
of TGF-b which may over-ride the normal inhibitory regula-
tion. It is thus likely that a mixture of positive cytokine
signals and the loss of negative or reguatory signals is
required for the development of KS.
Interactions with cells of the immune system
Three major cell types interact with endothelial cells (EC);
neutrophils, monocytes and lymphocytes. Neutrophils dyna-
mically interact with EC and cross into the extravascular
space. During inflammation neutrophils home to EC's a
process involving the expression of adhesive ligands on leu-
kocytes and induced expression of receptors on EC. Many of
these have been characterised and are reviewed elsewhere
(Harlan, 1985; Pober, 1988). Unlike neutrophils, monocytes
do not appear to mediate damage to EC's although they may
be able to significantly influence EC cell growth by secreting
both positive factors (GM-CSF) and negative ones (a-Inter-
feron).
Lymphocytes readily emigrate to sites of inflammation and
leave the blood by adhering to and migrating through the
endothelium lining specialised venules, particularly, though
not exclusively, the morphologically distinct high-endothelial
venules (HEV). The characteristics of which may depend
upon the presence of certain lymphocytes themselves!
(Streeter et al., 1988). In addition to leukocytes homing in on
EC's and influencing their growth and function (which
may include fatally damaging them), ECs may significantly
influence leukocytes. For instance, numerous factors and
cytokines may activate ECs which will then express MHC
class II molecules which will present antigen to T helper cells,
and readily induce an allogenic response (Pober, 1988).
The interactions between cells of the immune system and
ECs are clearly complex and different facts have been used to
describe EC changes in inflammation, vasculitis and athero-
sclerosis. So which features may be more pertinent to the
pathology of KS?
KS cells appear to be of endothelial origin and are consis-
tent with activated EC cells. Indeed human monokines and
cytokines from HIV negative patients with induce endothelial
cell elongation which resembles the KS spindle cell. More-
over, activation is clearly lymphokine dependent (Groen-
wegen et al., 1985; Fitzgerald et al., 1987; Majewski et al.,
1987; Bussolino et al., 1989). Other cells apart from lympho-
cytes can secrete EC inhibitory factors and an equilibrium of
these factors (i.e. stimulatory and inhibitory) in the absence
of immunosuppression is clearly required for normal EC
growth and function. In HIV infection selective depletion of
lymphocyte function occurs early in the disease (Dalgleish et
al., 1990). A number of studies have shown that the virus is
able to interfere with antigen specific presentation (Manca et
al., 1990). Therefore in KS it is possible that lymphocyte
subsets which exert a negative controlling influence on EC
proliferation are deleted. Growth factors such as these pro-
duced by a variety of cells including the HTLV-II infected
cell line described above could lead to KS. Moreover a
variety of viruses and micro-organisms have been proposed
as having a causative role in KS which only supports the
contention that the stimulatory axis of KS need not be
specific.
HIV and the immune system
In addition to the 'global' immunosuppression engendered by
the declining CD4 T helper cells, and the deletion of antigen
specific subsets of T cells there is another poorly understood
element which may affect the appearance of KS. HIV infect-
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ed patients have non specifically activated immune systems as
manifested by hypergammaglobulinaemia which is often
restricted (oligoclonal) in quality (Habeshaw & Dalgleish,
1989). This is accompanied by elevated cytokines which may
be stimulatory to EC cells. This non specific activation may
be due to infected HIV cells expressing growth factors or it
may be similar to the activation seen in chronic allogeneic
disease or graft vs host disease (GVHD). It has been postu-
lated that HIV could induce a GVH like disease by virtue of
resembling a foreign MHC (Habeshaw et al., 1990). If this is
so then immunological abnormalities associated with the
dysregulation seen in GVHD (including the elevation of a
number of cytokines) could further perturbate the immune
system in a manner which could favour the development of
KS.
Treatment ofKS
Treatment of KS depends upon the type and whether or not
it is HIV related. Classical KS readily responds to minimal
radiotherapy and chemotherapy (Odajnyk, 1985). However,
it usually progresses so slowly that treatment is usually only
given for cosmetic reasons. KS associated with HIV may also
only require cosmetic treatment. Individual lesions may be
unsightly even though they are neither aggressive of invasive.
For instance the tip of the nose is a common site for KS and
radiotherapy is of considerable cosmetic values. Systemic
treatment often has to be considered in HIV infected individ-
uals as lesions on the face and palate (another common site
where RT may relieve unpleasant symptoms), often herald
the involvement of the gastrointestinal tract and other
visceral involvement. Apart from local treatment systemic
treatment may be subdivided in (1) Anti-HIV treatment such
as AZT (Zidovudine), (2) Systemic chemotherapy, (3)
Immunomodulators such as interferon which also have anti-
viral properties.
KS in the present of HIV infection constitutes a diagnosis
of AIDS which is usually, but not always, associated with
advanced depletion of the immune system. Not surprisingly,
AZT does not work well at this stage although AZT assoc-
iated regression has been seen. Chemotherapy is limited by
side effects to which AIDS patients are very vulnerable. In
particular, chemotherapeutic neutropenia may be particularly
ominous. Chemotherapeutic trials performed in Africa have
suggested that vinblastine alone may be preferable to com-
bination regimes such as Doxorubicin, bleomycin and vin-
blastine (ABV) because of the high incidence of opportunistic
infections seen with the combination ABV (reviewed in Dalg-
leish, 1985). However a randomised trial in the US compar-
ing ABV with etopiside (VP-16) and vinblastine as single
agents showed a higher complete and partial response for
ABV (84%) than etopiside and vinblastine alone (76% and
27%, respectively - although 50% had stable disease with
vinblastine alone) (Lambeustein et al., 1989; Volberding et
al., 1985). Chemotherpay may also be given intralesionally
with some success. Interferon a (not P or a) has some effect
on KS, but only at high doses (>36 million units) which
suggests that it is acting as an antiproliferative agent.
Although response rates of up to 40% have been reported,
the doses required are associated with substantial toxicity.
Combination studies of interferon with AZT and chemo-
therapy are in progress (Levine, 1990).
The increasing understanding of the basic biology of KS
suggests that KS might be attacked either by eliminating the
hosts response to the process of proliferation in endothelial
cells, or by reducing the initial stimulus or by correcting the
underlying immune defect. The latter is probably the most
important in HIV infected patients as it is seen in transplan-
tation patients where withdrawing immunosuppression is
usually associated with complete regression. Even eliminating
all HIV infection may not lead to any significant change in
the immune response as the immune balance has been severe-
ly altered either indirectly or by clonal deletion of CD4 cells.
In the meantime, careful study of KS with and without HIV
infection is required for a better understanding of the aetio-
logy of KS.
Conclusions and future prospects
KS is not a one hit disease, but is the end product of a
complex interplay between cellular proliferative and control
systems which strongly invoke overall immunological control.
It is most serious in the presence of HIV infection and the
greatest relevance in its treatment would be to eliminate HIV
and reverse the associated change to the immune system. In
the presence of HIV infection, treatment is complicated by
the fact that it adds to the pre-existing immunosuppression.
Treatment for KS in HIV negative patients is much easier
and the biggest decision is when to treat.
Perhaps understanding the basic biology of KS at the cell
and molecular level may throw new insights into the patho-
genesis not only of KS, but also other proliferative diseases.
I would like to thank A. Kaul (London Hospital) for sharing
valuable data and discussions which will be included in a forthcom-
ing supplement of molecular aspects of medicine; AIDS.
References
BAYLEY, A.C., DOWNING, R.G., CHEINGSONG-POPOV, R., TEDDER,
R.S., DALGLEISH, A.G. & WEISS, R.A. (1985). HTLV- 111 serology
distinguishes atypical and endemic Kaposi's sarcoma in Africa.
Lancet, i, 359.
BERAL, V., PETERMAN, T.A., BERKELMAN, R.L. & JAFFE, H.W.
(1990). Kaposi's sarcoma among persons with AIDS: a sexually
transmitted infection? Lancet, i, 123.
BUSSOLINO, F., WANG, J.M., DEFILIPPI, P. & 6 others (1989).
Granulocyte- and granulocyte-macrophage- colony stimulating
factors induce human endothelial cells to migrate and proliferate.
Nature, 337, 471.
DALGLEISH, A.G. (1985). Human retroviruses. Aust. NZ J. Med., 15,
375.
DALGLEISH, A.G., HABESHAW, J. & MANCA, F. (1990). The patho-
genesis of AIDS. In AIDS and the New Viruses Dalgleish, A.G. &
Wiess, R.A. (eds). Academic Press: London.
DARROW, W.W., ECHENBERG, D.F., JAFFE, H.W. & 6 others (1987).
Risk factors for human immunodeficiency virus infection in
homosexual men. Am. J. Publ. Health, 77, 479.
ENSOLI, B., NAKAMURA, S., SALAHUDDIN, S.Z. & 5 others (1989).
AIDS-Kaposi's sarcoma-derived cells express cytokines with
autocrine and paracrine growth effects. Science, 243, 223.
FITZGERALD, O.M., HESS, E.V., CHANCE, A. & HIGHSMITH, R.F.
(1987). Quantitative studies of human monokine-induced endo-
thelial cell elongation. J. Leukocyte Biol., 41, 421.
FOLKMAN, J. (1986). How is blood vessel growth regulated in nor-
mal and neoplastic tissues? Can. Res., 46, 283.
FRIEDMAN-KIEN, A.E., SALTZMAN, B.R., LAO, Y. & 4 others (1990).
Kaposi's sarcoma in HIV negative homosexual men. Lancet, 335,
168.
GIRALDO, G., BETH, E. & HUANG, E.S. (1980). Kaposi's sarcoma
and its relationship to cytomegalovirus (CMV). III. CMV DNA
and CMV early antigens in Kaposi's sarcoma. Int. J. Cancer, 26,
23.
GOEDERT, J.J., BIGGAR, R.J., MELBYE, M. & 8 others (1986). Effect
of T4 count and cofactors on incidence of AIDS in homosexual
men infected with human immunodeficiency virus. JAMA, 257,
331.
GROENEWEGEN, G., BUURMAN, W.A. & VAN DER LINDEN, C.J.
(1985). Lymphokines induce changes in morphology and enhance
motility of endothelial cells. Clin. Immunol. & Immunopath., 36,
378.
HABESHAW, J. & DALGLEISH, A.G. (1989). The relevance of HIV
envelope/CD4 interactions to the pathogenesis of AIDS. J. AIDS,
2, 457.
HABESHAW, J., DALGLEISH, A.G., BOUNTIFF, L. & 4 others (1990).
AIDS pathogenesis; the role of cellular ligands in HIV infection.
Immunol. Today, 11, 618.
HARLAN, J.M. (1985). Leukocyte-endothelial interactions. Blood, 65,
513.
6 A.G. DALGLEISH
HAVERKOS, H.W., PINSKY, P.F., DROTMAN, D.P. & BREGMAN, D.J.
(1985). Disease manifestation among homosexual men with
acquired immunodeficiency syndrome: a possible role of nitrates
in Kaposi's sarcoma. Sex Transm. Dis., 12, 203.
HAVERKOS, H.W. (1987). Factors associated with the pathogenesis of
AIDS. J. Infect. Dis., 156, 251.
LEVINE, A.M. (1990). Therapeutic approaches to neoplasms in AIDs.
Rev. Inf. Dis., 12, 5.
LO, S.C. (1986). Isolation and identification of a novel virus from
patients with AIDS. Am. J. Trop. Med. Hyg., 35, 675.
MAJEWSKI, S., TIGALONWA, M., JABLONSKA, S., POLAKOWSKI, I.
& JANCZURA, E. (1987). Serum samples from patients with active
psoriasis enhance lymphocyte induced angiogenesis and modulate
endothelial cell proliferation. Arch. Dermatol., 123, 221.
MANCA, F., HABESHAW, J. & DALGLEISH, A.G. (1990). HIV enve-
lope glycoprotein antigen specific T cell responses and soluble
CD4. Lancet, i, 811.
MANN, D.L., MURRAY, C., O'DONNELL, M., BLATTNER, W.A. &
GOEDERT, J.J. (1990). HLA Antigen frequencies in HIV-1 related
Kaposi's sarcoma. J. AIDS, 1 (Suppl), 551.
MATHUR-WAGH, U., MILDVAN, D. & SENIE, R.T. (1985). Follow-up
at 4 1/2 years on homosexual men with generalised lymphadeno-
pathy. N. Engl. J. Med., 313, 1542.
NAKAMURA, S., SALAHUDDIN, S.Z. & BIBERFELD, P. & 4 others
(1988). Kaposi's sarcoma cells: long-term culture with growth
factor from retrovirus-infected CD4 + T cells. Science, 242, 426.
OSMOND, D., MOSS, A.R., BACHETTI, P., VOLBERDING, P., BARRIE-
SINOUSSI, F. & CHERMAN, J.E. (1985). A case-control study of
risk factors for AIDS in San Francisco. Presented at the 1st
International Conference on Acquired Immunodeficiency Syndrome
(AIDS), Atlanta, April 14-17.
PAPASTERIADES, C., KALOTERAKIS, A., FILIOTUO, A. & 5 others
(1984). Histocompatibility antigens HLA-A, B, DR in Greek
patients with Kaposi's sarcoma. Tissue Antigens, 24, 313.
PENN, I. (1979). Kaposi's sarcoma in organ transplant recipients.
Report of 20 cases. Transplanation, 27, 8.
PENN, I. (1983). Kaposi's sarcoma in immunosuppressed patients. J.
Clin. Lab. Immunol., 11, 47.
POBER, J.S. (1988). Cytokine-mediated activation of vascular endo-
thelium. Am. J. Pathol., 133, 426.
POLK, F., FOX, R., BROOKMEYER, R. & 5 others (1987). Predictors
of the acquired immunodeficiency syndrome developing in a
cohort of seropositive men. N. Eng. J. Med., 316, 62.
POLLACK, M.S., SAFAI, B., MYSKOWSKI, P.L., GOLD, J.W.M.,
PANDEY, J. & DUPONT, B. (1983a). Frequencies of HLA and Gm
immunogenetic markers in Kaposi's sarcoma. Tissue Antigens, 21,
1.
POLLACK, M.S., SAFAI, B. & DUPONT, B. (1983b). HLA-DR5 and
DR2 susceptibility factors for acquired immunodeficiency syn-
drome patients with Kaposi's sarcoma in different ethnic sub-
populations. Dis. Markers, 1, 135.
POLLACK, M.S. & RICH, R.R. (1985). The HLA complex and the
pathogenesis of infectious disease. J. Infect. Dis., 151, 1.
RAPPERSBERGER, K., TSCHALCHLER, E., ZONZITS, E. & 10 others
(1990). Endemic KS in HIV-1 negative persons demonstration of
retrovirus like particles in cutaneous lesions. J. Invest. Dermatol.,
95, 371.
RUTHERFORD, G.W., PAYNE, S.F. & LEMP, G.F. (1990). The epi-
demiology of AIDS related Kaposi's sarcoma in San Francisco.
J. AIDS, 3 (Suppl), 54.
SALAHUDDIN, S.Z., NAKAMURA, S., BIBERFIELD, P. & 4 others
(1988). Angiogenic properties of Kaposi's sarcoma-derived cells
after long-term, culture in vitro. Science, 242, 430.
SERWADDA, D., MUGERWA, R.D., SEWANKAMBO, N.K. & 9 others
(1985). Slim disease: a new disease in Uganda and its association
with HTLV-111 infection. Lancet, ii, 849.
STREETER, P.R., BERG, E.L., ROUSE, N., BORGATZE, R. & BUT-
CHER, E.C. (1988). A tissue specific endothelial cell molecule
involved in lymphocyte homing. Nature, 331, 41.
TEMPLETON, A.C. (1973). (ed.) Tumours in a Tropical Country.
Springer Verlag: Berlin.
VOGEL, J., HINRICHS, S.H., REYNOLDS, R.K., LUCISIS, P. & JAY, G.
(1988). The HIV tat gene induces dermal lesions resembling
Kaposi's sarcoma in transgenic mice. Nature, 335, 606.
ZEIGLER, J.L. & DORFMAN, R.F. (1988). (eds) Kaposi's Sarcoma.
Marcel Dekker: New York.
